Literature DB >> 12117922

Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role.

Sylvie Alonso1, Nathalie Reveneau, Kévin Pethe, Camille Locht.   

Abstract

Bordetella pertussis, the etiological agent of whooping cough, produces a number of factors, such as toxins and adhesins, that are required for full expression of virulence. Filamentous hemagglutinin (FHA) is the major adhesin of B. pertussis. It is a protein of approximately 220 kDa, found both associated at the bacterial cell surface and secreted into the extracellular milieu. Despite its importance in B. pertussis pathogenesis and its inclusion in most acellular pertussis vaccines, little is known about the functional importance of individual domains in infection and in the induction of protective immunity. In this study, we analyzed the role of the approximately 80-kDa N-terminal domain of FHA, designated Fha44, in B. pertussis adherence, colonization, and immunogenicity. Although Fha44 contains the complete heparan sulfate-binding domain, it is not sufficient for adherence to epithelial cells or macrophages. It also cannot replace FHA during colonization of the mouse respiratory tract. Infection with a B. pertussis strain producing Fha44 instead of FHA does not induce anti-FHA antibodies, whereas such antibodies can readily be induced by intranasal administration of purified Fha44. In addition, mice immunized with purified Fha44 were protected against challenge with wild-type B. pertussis, indicating that Fha44 contains protective epitopes. Compared to FHA, Fha44 is much smaller and much more soluble and is therefore easier to purify and to store. These advantages may perhaps warrant considering Fha44 for inclusion in acellular pertussis vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117922      PMCID: PMC128203          DOI: 10.1128/IAI.70.8.4142-4147.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

Review 1.  Two-partner secretion in Gram-negative bacteria: a thrifty, specific pathway for large virulence proteins.

Authors:  F Jacob-Dubuisson; C Locht; R Antoine
Journal:  Mol Microbiol       Date:  2001-04       Impact factor: 3.501

2.  Role of adhesins and toxins in invasion of human tracheal epithelial cells by Bordetella pertussis.

Authors:  L Bassinet; P Gueirard; B Maitre; B Housset; P Gounon; N Guiso
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

3.  Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial.

Authors:  J Storsaeter; H Hallander; C P Farrington; P Olin; R Möllby; E Miller
Journal:  Vaccine       Date:  1990-10       Impact factor: 3.641

4.  Both adenylate cyclase and hemolytic activities are required by Bordetella pertussis to initiate infection.

Authors:  N Khelef; H Sakamoto; N Guiso
Journal:  Microb Pathog       Date:  1992-03       Impact factor: 3.738

5.  Adenylate cyclase toxin is critical for colonization and pertussis toxin is critical for lethal infection by Bordetella pertussis in infant mice.

Authors:  M S Goodwin; A A Weiss
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

6.  Versatile suicide vectors which allow direct selection for gene replacement in gram-negative bacteria.

Authors:  J Quandt; M F Hynes
Journal:  Gene       Date:  1993-05-15       Impact factor: 3.688

7.  Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection.

Authors:  R D Shahin; D F Amsbaugh; M F Leef
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

8.  Identification and purification of transferrin- and lactoferrin-binding proteins of Bordetella pertussis and Bordetella bronchiseptica.

Authors:  F D Menozzi; C Gantiez; C Locht
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

9.  Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin.

Authors:  E S Cahill; D T O'Hagan; L Illum; K Redhead
Journal:  FEMS Microbiol Lett       Date:  1993-03-01       Impact factor: 2.742

10.  Common accessory genes for the Bordetella pertussis filamentous hemagglutinin and fimbriae share sequence similarities with the papC and papD gene families.

Authors:  C Locht; M C Geoffroy; G Renauld
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

View more
  15 in total

1.  Fusion expression and immunogenicity of Bordetella pertussis PTS1-FHA protein: implications for the vaccine development.

Authors:  Zhang Jinyong; Zhang Xiaoli; Zhang Weijun; Guo Ying; Guo Gang; Mao Xuhu; Zou Quanming
Journal:  Mol Biol Rep       Date:  2010-09-28       Impact factor: 2.316

2.  Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.

Authors:  J B Knight; Y Y Huang; S A Halperin; R Anderson; A Morris; A Macmillan; T Jones; D S Burt; G Van Nest; S F Lee
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

Review 3.  Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.

Authors:  Dorji Dorji; Frits Mooi; Osvaldo Yantorno; Rajendar Deora; Ross M Graham; Trilochan K Mukkur
Journal:  Med Microbiol Immunol       Date:  2017-11-21       Impact factor: 3.402

4.  Production of nontypeable Haemophilus influenzae HtrA by recombinant Bordetella pertussis with the use of filamentous hemagglutinin as a carrier.

Authors:  Sylvie Alonso; Eve Willery; Genevieve Renauld-Mongénie; Camille Locht
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

5.  Haemagglutination induced by Bordetella pertussis filamentous haemagglutinin adhesin (FHA) is inhibited by antibodies produced against FHA(430-873) fragment expressed in Lactobacillus casei.

Authors:  Débora Colombi; Maria L S Oliveira; Ivana B Campos; Vicente Monedero; Gaspar Pérez-Martinez; Paulo L Ho
Journal:  Curr Microbiol       Date:  2006-11-13       Impact factor: 2.188

6.  Hemagglutinin B is involved in the adherence of Porphyromonas gingivalis to human coronary artery endothelial cells.

Authors:  Hong Song; Myriam Bélanger; Joan Whitlock; Emil Kozarov; Ann Progulske-Fox
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

7.  The Bps polysaccharide of Bordetella pertussis promotes colonization and biofilm formation in the nose by functioning as an adhesin.

Authors:  Matt S Conover; Gina Parise Sloan; Cheraton F Love; Neelima Sukumar; Rajendar Deora
Journal:  Mol Microbiol       Date:  2010-07-30       Impact factor: 3.501

8.  Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates.

Authors:  Si Ying Ho; Shi Qian Chua; Damian G W Foo; Camille Locht; Vincent T Chow; Chit Laa Poh; Sylvie Alonso
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

9.  Construction and characterization of single-chain variable fragment antibodies directed against the Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin.

Authors:  Ahmad H Hussein; Elisabeth M Davis; Scott A Halperin; Song F Lee
Journal:  Infect Immun       Date:  2007-08-27       Impact factor: 3.441

Review 10.  Bordetella filamentous hemagglutinin and fimbriae: critical adhesins with unrealized vaccine potential.

Authors:  Erich V Scheller; Peggy A Cotter
Journal:  Pathog Dis       Date:  2015-09-27       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.